Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing various ways to treat inflammatory and immune-related diseases. The Company's most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. It is evaluating EB05 in a Phase III study as a potential treatment for acute respiratory distress syndrome, a life-threatening form of respiratory failure. EB05 has also been included in a United States government funded platform study of host directed therapeutics. It has received Canadian regulatory approval to conduct a Phase II trial its EB06 (anti-CXCL10) monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. It is developing an sPLA2 inhibitor, EB01 (1.0% daniluromer cream), as a topical treatment for chronic Allergic Contact Dermatitis, a common occupational skin condition.

• Revenue in USD (TTM)0.00
• Net income in USD-6.93m
• Incorporated2009
• Employees16.00

• Location
  Edesa Biotech Inc100 Spy CrtMARKHAM L3R 5H6CanadaCAN
• Phone+1 (905) 475-1234
• Fax+1 (905) 475-1234
• Websitehttps://www.edesabiotech.com/